<DOC>
	<DOCNO>NCT01190150</DOCNO>
	<brief_summary>This Phase 4 , randomize , 2-way crossover , pharmacokinetic study Lysteda ( tranexamic acid ) tablet administer single dos 0.65 g 1.3 g fast adolescent female subject age 12-16 year heavy menstrual bleeding .</brief_summary>
	<brief_title>Lysteda Pediatric Research Equity Act ( PREA ) Pharmacokinetic Study Adolescent Females With Heavy Menstrual Bleeding</brief_title>
	<detailed_description />
	<mesh_term>Menorrhagia</mesh_term>
	<mesh_term>Tranexamic Acid</mesh_term>
	<criteria>Generally healthy nonsmoking ( least 3 month ) adolescent female 1216 year age history least 1 year cyclic heavy menstrual bleeding ( HMB ) Subjects must report regularly occur menstrual period â‰¤10 day duration , 2145 day start one period start next menstrual period Diagnosis HMB base medical judgment Principal Investigator include follow criterion : 1 . Laboratory ( include bleed disorder workup ) Physical Findings ; 2 . Limitations Activities Daily Living ( ADL ) ; 3 . Soiling , Staining Clotting ; 4 . Sanitary product usage extent MBL use patient report pictorial blood assessment chart ( PBAC ) . Subjects either sexually inactive ( abstinent ) use one follow acceptable birth control method agree continue use throughout study : copper intrauterine device ( IUD ) place least 3 month ; barrier method ( condom , diaphragm ) spermicide least 1 month prior first dose throughout study . Negative pregnancy test result Subject 's legally authorize representative ( e.g. , parent , guardian ) must voluntarily sign parental permission/informed consent form ( ICF ) , subject must sign assent , conduct study procedure Breastfeeding , history abortion last 6 month Known bleed coagulation disorder base medical history and/or laboratory result Known systemic hematologic disease ( e.g. , type sicklecell disease , thalassemia type , multiple myeloma , hemolytic anemia ) Clinical evidence significant chronic illness , include cardiovascular , renal , neurologic , hepatic , endocrine , gastric , central nervous system disease , psychiatric illness could affect efficacy safety study medication Subjects treat systemic steroid last 1 month hormonal treatment last 3 month A history presence drug abuse alcohol abuse within last 1 year History subarachnoid hemorrhage . Active thromboembolic disease ; history thrombosis thromboembolism , include retinal vein artery occlusion ; intrinsic risk thrombosis thromboembolism Use vaginal hormone product ( ring , cream , gel ) within 4 week prior screen . Use oral estrogen , progestin , selective estrogen receptor within 8 week prior screen . Use Lupron ( 3month depot injection ) , estrogen pellet , longacting progestin injectables within 6 month prior screen Subjects whose sit blood pressure le 90/60 mmHg screen Subjects whose pulse low 50 b.p.m . screen Subjects whose PR interval &gt; 200 msec screen prior dose Subjects whose QTc interval &gt; 450 msec Subjects positive test hepatitis B , C , human immunodeficiency virus ( HIV )</criteria>
	<gender>Female</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Cyclic Heavy Menstrual Bleed</keyword>
	<keyword>Menorraghia</keyword>
</DOC>